Electrochemotherapy: Progress and prospects

Current Pharmaceutical Design

Volumn 18, Issue 23, 2012, Pages 3406-3415

  Escoffre, Jean Michel ^a,b,c   Rols, Marie Pierre ^b,c  

^a UNIVERSITÉ DE TOURS   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

^c UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Bleomycin; Cisplatin; Clinical trials; Electrochemotherapy; Electropermeabilization

Indexed keywords

BLEOMYCIN; CISPLATIN; MITOCHONDRIAL DNA;

ADAPTIVE IMMUNITY; ARTICLE; CELL MEMBRANE STEADY POTENTIAL; CELL PERMEABILIZATION; CYTOPLASM; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG POTENTIATION; DRUG TRANSPORT; DRUG TUMOR LEVEL; ELECTRIC FIELD; ELECTROCHEMOTHERAPY; ELECTROPHOTODYNAMIC THERAPY; ELECTROPORATION; ENDOCYTOSIS; ENDOPLASMIC RETICULUM STRESS; IMMUNE RESPONSE; INNATE IMMUNITY; IRREVERSIBLE ELECTROPORATION; MEMBRANE TRANSPORT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR IMMUNITY;

CELL MEMBRANE PERMEABILITY; CLINICAL TRIALS AS TOPIC; ELECTROCHEMOTHERAPY; HUMANS; SKIN NEOPLASMS;

EID: 84863525385     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801227087     Document Type: Article

References (108)

1. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Advances in Genetics 2005; 54: 3-20.
2. Escoffre JM, Teissié J, Rols MP. Gene transfer: How can the biological barriers be overcome. J Membr Biol 2010; 236: 61-76.
3. Sajja HK, East MP, Mao H, Wang YA, Nie S, Yang L. Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol 2009; 6: 43-51.
4. Villemejane J, Mir LM. Physical methods of nucleic acid transfer: general concepts and applications. Br J Pharmacol 2009; 157: 207-19.
5. Neumann E, Sowers AE, Jordan CA. Electroporation and electrofusion in cell biology 1989; Plenum, New York.
6. Golzio M, Escoffre JM, Portet T, et al. Observations of the mechanisms of electromediated DNA uptake-from vesicles to tissues. Curr Gene Ther 2010; 10: 256-66.
7. Golzio M, Rols MP, Teissie J. In vitro and in vivo electric fieldmediated permeabilization, gene transfer, and expression. Methods 2004, 33; 126-35.
8. Casabianca-Pignède, M-R, LM Mir, JB Le Pecq, A Jacquemin-Sablon. Stability of antiricin antibodies introduced into DC-3F Chinese hamster cells by electropermeabilization. J Cell Pharmacol 1991; 2: 54-60.
9. Orlowski S, Belehradek J Jr, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture; increase in cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727-33.
10. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-40.
11. Daud Al, DeConti RC, Andrews S, et al. Phase I trial of interleukin- 12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903.
12. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-78.
13. Garcia PA, Neal RE, Rossmeisl JH, Davalos RV. Non-thermal irreversible electroporation for deep intracranial disorders. Conf Proc IEEE Eng Med Biol Soc 2010; 1: 2743-46.
14. Mir LM, Belehradek M, Domenge C, et al. Electrochemotherapy, a new antitumor treatment: first clinical trial. CR Acad Sci III 1991; 313: 613-8.
15. Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study: advantages and clinical uses. Eur J Cancer Suppl 2006; 4: 52-9
16. Byrne CM, Thompson JF. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Experts Rev Anticancer Ther 2006; 6: 671-8.
17. Bernhardt J, Pauly H. On the generation of potential differences across the membranes of ellipsoidal cells in an alternating electrical field. Biophysik 1973; 10: 89-98.
18. Kotnik T, Miklavcic D. Analytical description of transmembrane voltage induced by electric fields on spheroidal cells. Biophys J 2000; 79: 670-9.
19. Hibino M, Itoh H, Kinosita K Jr. Time courses of cell electroporation as revealed by submicrosecond imaging of transmembrane potential. Biophys J 1993; 64: 1789-800.
20. Pucihar G, Kotnik T, Valic B, Miklavcic D. Numerical determination of transmembrane voltage induced on irregularly shaped cells. Ann Biomed Eng 2006; 34: 642-52.
21. Hibino M, Shigemori M, Itoh H, Nagayama K, Kinosita K Jr. Membrane conductance of an electroporated cell analyzed by submicrosecond imaging of transmembrane poten-tial. Biophys J 1991; 59: 209-20.
22. Teissié J, Rols MP. An experimental evaluation of the critical potential difference inducing cell membrane electropermeabilization. Biophys J 1993; 65: 409-13.
23. Gabriel B, Teissié J. Direct observation in the millisecond time range of fluorescent molecule asymmetrical interaction with the electropermeabilized cell membrane. Biophys J 1997; 73: 2630-7.
24. Valic B, Golzio M, Pavlin M, et al. Effect of electric field induced transmembrane potential on spheroidal cells: Theory and experiment. Eur Biophys J 2003; 32: 519-528.
25. Rols MP, Teissie J. Electropermeabilization of mammalian cells. Quantitative analysis of the phenomenon. Biophys J 1990; 58: 1089-98.
26. Gabriel B, Teissie J. Time courses of mammalian cell electropermeabilization observed by millisecond imaging of membrane property changes during the pulse. Biophys J 1999; 76: 2158-65.
27. Teissie J, Golzio M, Rols MP. Mechanisms of cell membrane electropermeabilization: a minireview of our present (lack of) knowledge? Biochim Biophys Acta 2005; 1724: 270-80.
28. Golzio M, Teissie J, Rols MP. Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci USA 2002; 99: 1292-7.
29. Escoffre JM, Portet T, Favard C, Teissié J, Dean DS, Rols MP. Electromediated formation of DNA complexes with cell membranes and its consequences for gene delivery. Biochim Biophys Acta 2010; 1808: 1538-43.
30. Rols MP, Teissie J. Electropermeabilization of mammalian cells to macromolecules: Control by pulse duration. Biophys J 1998; 75: 1415-23.
31. Pucihar G, Kotnik T, Miklavcic D, Teissié J. Kinetics of transmembrane transport of small molecules into electropermeabilized cells. Biophys J 2008; 95: 2837-48.
32. Mir LM. Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl 2006; 11: 38-44.
33. Pron G, Mahrour N, Orlowski S, et al. Internalization of the bleomycin molecules responsible for bleomycin toxicity: a receptormediated endocytosis mechanism. Biochem Pharmacol 1999; 57: 45-56.
34. Cullen KJ, Yang Z, Schumaker L, Guo Z. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J Bioenerg Biomembr 2007; 39: 43-50.
35. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. Is cisplatininduced cell death always produced by apoptosis. Mol Pharmacol 2001; 59: 657-63.
36. Sersa G, Cemazar M, Miklavcic D. Antitumor effectiveness of electrochemotherapy with cis-platinum(II) in mice. Cancer Res 1995; 55: 3450-5.
37. Sersa G, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy of tumours. Radiol Oncol 2006; 40: 163-74.
38. Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumor blood flow changes induced by application of electric pulses. Eur J Cancer 1999; 35: 672-7.
39. Sersa G, Cemazar M, Miklavcic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999; 19(5B): 4017-22.
40. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002; 1569: 51-8.
41. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-36.
42. Sersa G, Krzic M, Sentjurc M, Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002; 87: 1047-54.
43. Orlowski S, An D, Belehradek J Jr, Mir LM. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2- secreting cells in the murine Lewis lung tumor. Anticancer Drugs 1998; 9: 551-6.
44. Sersa G, Miklavcic D, Cemazar M, Belehradek J Jr, Jarm T, Mir LM. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochem Bioenerg 1997; 43: 279-83.
45. Heller L, Pottinger C, Jaroszeski MJ, Gilbert R, Heller R. In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res 2000; 10: 577-583.
46. Sersa G, Cemazar M, Menart V, Gaberc-Porekar V, Miklavcic D. Antitumor effectiveness of electrochemotherapy in increased by TNF-. on SA-1 tumors in mice. Cancer Lett 1997; 116: 85-92.
47. Cemazar M, Jarm T, Sersa G. Cancer electrogene therapy with interleukin-12. Curr Gene Ther 2010, 10: 300-11
48. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneaous and subcutaneaous malignant tumours by electrochemotherapy. Br J Cancer 1998; 77: 2336-42.
49. Heller R, Jarodszeski M, Perrott R, Messina J, Gilbert R. Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res 1997; 7: 10-18.
50. Sersa G, Stabuc B, Cemazar C, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6; 863-7.
51. Bloom DC, Goldfarb PM. The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamius cell carcinoma of the head and neck. Eur J Surg Oncol 2005; 31: 1029-35.
52. Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res 2005; 15: 45-51.
53. Sersa G. The state-of-the-art of electrochemotherapy before the ESOPE study: advantages and clinical uses. Eur J Cancer Suppl 2006; 4: 52-9.
54. Mir LM, Gehl J, Sersa G et al., Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006; 4: 14-25.
55. Domenge C, Orlowski S, Ludoinski B, De Baere T, Belehradek Jr J, Mir LM. Antitumor electrochemotherapy: new advances in the clinical protocol. Cancer 1996; 77: 956-63.
56. Cemazar M, Milacic R, Miklavcic D, Dolzan V, Sersa G. Intratumoral cisplatin administration in electrochemotherapy: antitumor effectiveness, sequence and platinum content. Anticancer Drugs 1998; 9: 525-30.
57. Tozon N, Kore V, Sersa G, Cemazar M. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res 2005; 25: 839-46.
58. Spugini EP, Renaud SM, Buglioni S, et al. Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs. J Transl Med 2011; 9: 152.
59. Marty M, Sersa G, Garbay JR et al. Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 2006; 4: 3-13.
60. Miklavcic D, Corovic S, Pucihar G, Pavselj N. Importance of tumour coverage by sufficiently high local electric field for effective electrochemotherapy. Eur J Cancer Suppl 2006; 4: 45-51.
61. Puc M, Corovic S, Flisar K, Petkovsek M, Nastran J, Miklavcic D. Techniques of signal generation required for electropermeabilization: survey of electropermeabilization devices. Bioelectrochemistry 2004; 64: 113-24.
62. Pavselj N, Bregar Z, Cukjati D, Batiuskaite D, Mir LM, Miklavcic D. The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans Biomed Eng 2005; 52: 1373-81.
63. Snoj M, Cemazar M, Slekovec Kolar B, Sersa G. Effective treatment of multiple unresectable skin melanoma mestastases by electrochemotherapy: case report. Croat Med J 2007; 48: 345-9.
64. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J Jr, Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72: 3694-700.
65. Heller R, Jaroszeski MJ, Glass LF, et al. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 1996; 132: 964-971.
66. Glass LF, Fenske NA, Jaroszeski M, et al. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol 1996; 82-6.
67. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous ad subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 83: 148-57.
68. Kubota Y, Mir LM, Nakada T, Sasagawa I, Suzuki H, Aoyama N. Successful treatment of metastatic skin lesions with electrochemotherapy. J Urol 1998; 160: 1426.
69. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: potentiation of local cisplatin antitumor effectiveness by application of electric pulses in cancer patients. Eur J Cancer 1998; 34: 1213-4.
70. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roché H, Teissié J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res 2000; 10: 468-74.
71. Gehl J, Geertsen PF. Efficient palliation of haemorrhaging malignant melanoma skin metastases by electrochemotherapy. Melanoma Res 2000; 10: 585-9.
72. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: the systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res 2000; 10: 381-5.
73. Rodriguez-Cuevas S, Barroso-Bravo S, Almanza-Estrada J, Cristobal- Martinez L, Gonzalez-Rodriguez E. Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin. Arch Med Res 2001; 32: 273-6.
74. Allegretti JP, Panje WR. Electroporation therapy for head and neck cancer including carotid artery involvement. Laryngoscope 2001; 111: 52-56.
75. Shimizu T, Nikaido T, Gomyo H, et al. Electrochemotherapy for digital chondrosarcoma. J Orthop Sci 2003; 8: 248-51.
76. Rebersek M, Cufer T, Cemazar M, Kranjc S, Sersa G. Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer drugs 2004; 15: 593-7.
77. Snoj M, Rudolf Z, Cemazar M, Jancar B, Sersa G. Successful sphincter-saving of anorectal malignant melanoma with electrochemotherapy, local excision and adjuvant brachytherapy. Anticancer Drugs 2005; 16: 345-8.
78. Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115-21.
79. Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma mestastases. Ann Surg Oncol 2008; 15: 2215-22.
80. Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol 2009; 16: 191-9.
81. Landström FJ, Nilsson COS, Crafoord S, Reizenstein JA, Gun-Britt MA, Löfgren LA. Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg 2010; 36: 1245-50.
82. Kaehler KC, Egberts F, Hauschild A. Electrochemotherapy in symptomatic melanoma skin metastases: Intraindividual comparison with conventional surgery. Dermatol Surg 2010; 35: 1200-2.
83. Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik K, Sersa G. Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiol Oncol 1995; 29: 229-35.
84. Glass LF, Fenske NA, Jaroszeski M, et al. Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol 1996; 34: 82-86.
85. Glass LF, Jaroszeski M, Gilbert R, Reintgen DS, Heller R. Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol 1997; 37: 596-9.
86. Panje WR, Hier MP, Garman, Harrell E, Goldman A, Bloch I. Electroporation therapy of head and neck cancer. Ann Otol Rhinol Laryngol 1998; 107: 779-85.
87. Sersa G, Cufer T, Cemazar M, Rebersek M, Zvonimir R. Electrochemotherapy with bleomycin in the treatment if hypernephroma metastasis: case report and literature review. Tumori 2000; 86: 162-5.
88. Burian M, Formanek M, Regele H. Electroporation therapy in head and neck cancer. Acta Otolaryngol 2003; 123: 264-8.
89. Sersa G, Cemazar M, Rudolf Z. Electrochemotherapy: advantages and drawbacks in treatment of cancer patients. Cancer Ther 2003; 1: 133-42.
90. Testori A, Tosti G, Martinoli C, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: novel therapeutic approach. Dermatol Ther 2010; 23: 651-61.
91. Soden DM, Larkin JO, Collins CG, et al. Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett 2006; 232: 300-10.
92. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustess of a new electrode device for intracranial tumor electroporation. Bioelectrochem 2011; 81: 10-16.
93. Kos B, Zupanic A, Kotnik T, Snoj M, Sersa G, Miklavcic D. Robustess of treatment planning for electrochemotherapy of deepseated tumors. J Membr Biol 2010; 236: 147-53.
94. Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G. Radiosensitizing effect of electrochemotherapy in a fractionated radiation regimen in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model. Radiat Res 2009; 172: 677-85.
95. Kranjc S, Cemazar M, Grosel A, Senjurc M, Sersa G. Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice. BMC Cancer 2005; 5: 115.
96. Sersa G, Kranjc S, Cemazar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 2000; 46: 1037-41.
97. Labanauskiene J, Satkauska S, Kirveliene V, Venslauskas M, Atkocius V, Didziapetriene J. Enhancement of photodynamic tumor therapy effectiveness by electroporation in vitro. Medicina 2009; 45: 372-7.
98. Labanauskiene J, Gehl J, Didziapetriene J. Evaluation of cytotoxic effect of photodynamic therapy in combination with electroporation. Bioelectrochem 2007; 70: 78-82.
99. Saczko J, Nowak M, Skolucka N, Kulbacka J, Kotulska M. The effects of the electro-photodynamic in vitro treatment on human lung adenocarcinoma cells. Bioelectrochem 2010; 79: 90-4.
100. Davalos RV, Mir LM, Rubinsky NB. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33: 223-31.
101. Maor E, Ivorra A, Leor J, Rubibsky B. The effect of irreversible electroporation on blood vessels. Technol Cancer Res Treat 2007; 6: 307-312.
102. Onik G, Mikus P, Rubinsky B. Irreversible electroporation: Implications for prostate ablation. Technol Cancer Res Treat 2007; 6: 295-300.
103. K. Human experience with irreversible electroporation, in Rubinsky B (ed): Irreversible electroporation. Heidelberg, Germany, Springer Berlin 2010, pp 249-54.
104. Lee EW, Loh CT, Kee ST. Imaging guided percutaneous irreversible electroporation: Ultrasound and immunohistological correlation. Technol Cancer Res Treat 2007; 6: 287-93.
105. Rubinsky B, Onik G, Mikus P. Irreversible electroporation: A new ablation modality-Clinical implications. Technol Cancer Res Treat 2007; 6: 37-48.
106. Pech M, Janitzky A, Wendler JJ, et al. Irreversible electroporation of renal cell carcinoma: a first-in-man phase I clinical study. Cardiovasc Intervent Radiol 2011; 34: 32-138.
107. Onik G, Rubinsky B. Irreversible electroporation: First patient experience - Focal therapy of prostate cancer, in Rubinsky B (ed): Irreversible electroporation. Heidelberg, Germany, Springer Berlin 2010; pp 235-47.
108. Ball C, Thomson KR, Kavnoudias J. Irreversible electroporation: A new challenge in out of operating threater anesthesia. Anesth Analg 2010; 110: 1305-9.